COMMUNIQUÉS West-GlobeNewswire

-
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
19/01/2024 -
Venus Concept Inc. Announces Issuance of $2.0M of Convertible Notes
19/01/2024 -
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
19/01/2024 -
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
19/01/2024 -
Coloplast A/S - Q1 2023/24 Earnings Release - Invitation for conference call on 9 February 2024 at 11.00am CET
19/01/2024 -
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
19/01/2024 -
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
19/01/2024 -
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
19/01/2024 -
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
18/01/2024 -
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
18/01/2024 -
Kane Biotech Announces Special Meeting of Shareholders
18/01/2024 -
Aimei Health Technology Co., Ltd. Announces the Separate Trading of its Ordinary Shares and Rights Commencing January 22, 2024
18/01/2024 -
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
18/01/2024 -
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
18/01/2024 -
PHAXIAM Therapeutics annonce son niveau de trésorerie à fin 2023 et son calendrier financier 2024
18/01/2024 -
QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million
18/01/2024 -
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
18/01/2024 -
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
18/01/2024 -
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
18/01/2024
Pages